DUBLIN, IRELAND--(Marketwire - January 21, 2008) -

                         Alltracel Pharmaceuticals Plc
                         ('Alltracel or the 'Company')

                          Statement re: Possible Offer
Monday, January 21st 2008, Dublin, Ireland and London, UK

The Board of Alltracel has noted the recent press speculation and confirms that it has received a very preliminary approach from a third party which may or may not lead to an offer being made for the entire issued share capital of Alltracel.

It should be emphasised that discussions are at a very early stage and that there is no certainty that they will lead to an offer.

The holder of 1% or more of any relevant securities in the Company may from the date of this announcement have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2001 to 2005, as applied, with amendments by the European Communities (Takeover Bids (Directive 2004/25/EC)) Regulations 2006.

                        For Further Information Contact:

Dublin: Karen Muldowney Alltracel: +353 1 235 2162  press@alltracel.com
London: Deborah Scott/John Dineen Financial Dynamics: +44 207 831 3113
Des Carville Davy Corporate Finance: + 353 1 679 63 63

The Directors of Alltracel accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they take responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

                      This information is provided by RNS
            The company news service from the London Stock Exchange